[Preliminary clinic observation on the inhibition of HBV by receptor-targeted drug L-HSA-AraAMP].

摘要: To preliminarily observe the antiviral effect of receptor-targeted drug, Lactosaminated Human Serum Albumin Arabinoside Adenine Monophosphate (L-HSA-Ara-AMP), 10 patients with chronic type B hepatitis (HBsAg, HbeAg/HBV DNA positive) were treated this drug for 5 days. The daily dose L-HSA-Ara-AMP was 35 mg/Kg (containing 1.5 mg Ara-AMP), whereas usual free Ara-AMP is mg/Kg. In treated, three patients' HBeAg became negative and six titer fell. Anti-HBc IgM all in 4 anti-HBc positive patients. 8 HBV patients, four other decreased. HBsAg remained ten No adverse effects observed. results showed that inhibits as effective Ara-AMP, but at a 6.7 times lower than Ara-AMP.